BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 28389687)

  • 1. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Shustik C; Bence-Bruckler I; Delage R; Owen CJ; Toze CL; Coutre S
    Ann Hematol; 2017 Jul; 96(7):1185-1196. PubMed ID: 28389687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
    Rafei H; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):1-12. PubMed ID: 28549767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
    Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
    J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Targeted treatment of chronic lymphocytic leukaemia].
    Niemann CU
    Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
    Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
    Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
    Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
    J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
    Waldron M; Winter A; Hill BT
    Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
    Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
    Blood; 2016 Aug; 128(7):934-47. PubMed ID: 27297795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.
    Gaidano G; Rossi D
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):329-337. PubMed ID: 29222275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should we sequence and combine novel therapies in CLL?
    Davids MS
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current strategies to create tailored and risk-adapted therapies for CLL patients.
    Cramer P; Eichhorst B; Reinhardt HC; Hallek M
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal dynamics in chronic lymphocytic leukemia.
    Gutierrez C; Wu CJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):466-475. PubMed ID: 31808879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic lymphocytic leukaemia.
    Hallek M; Shanafelt TD; Eichhorst B
    Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
    Thijssen R; Ter Burg J; Garrick B; van Bochove GG; Brown JR; Fernandes SM; Rodríguez MS; Michot JM; Hallek M; Eichhorst B; Reinhardt HC; Bendell J; Derks IA; van Kampen RJ; Hege K; Kersten MJ; Trowe T; Filvaroff EH; Eldering E; Kater AP
    Blood; 2016 Jul; 128(4):574-83. PubMed ID: 27235137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.